We combine cutting-edge machine learning and biology to advance drug discovery.
Discover
Our substantial increase in the understanding of cancer has not yet led to better treatments for patients.
Challenges
How can we move from understanding the disease to discovering the treatment?
Disease heterogeneity
No two cancers are the same. From environmental factors to genetics, patients are all different, making it difficult to develop effective treatments.
Each cancer evolves differently
Cancer unfolds in a variety of ways across patients, calling for a personalized approach.
Under-utilization of knowledge
Researchers lack the powerful tools required to fully harness the vast potential of untapped scientific insights.
Disease heterogeneity
No two cancers are the same. From environmental factors to genetics, patients are all different, making it difficult to develop effective treatments.
Each cancer evolves differently
Cancer unfolds in a variety of ways across patients, calling for a personalized approach.
Under-utilization of knowledge
Researchers lack the powerful tools required to fully harness the vast potential of untapped scientific insights.
Owkin’s solution
We leverage our expert multimodal data access and deploy state-of-the-art, interpretable AI to refine our understanding of diseases to develop biomarkers and identify new drug targets. In addition, we build AI tools that match historical and emerging research to identify new drug combinations and opportunities for drug repurposing.
Advancing discovery
Drug target identification
We combine our expertise in AI and biology to fully interpret histogenomic biomarkers. This helps us discover and rank genes and proteins within the innovative drug target potential.
Drug combination
Using real-world data (genomic data, clinical trial results and literature), we build AI models that analyze disease mechanisms to identify possible drug combinations. These are designed to improve the efficiency of a client's drug candidate.
Drug repurposing
We build AI models that analyze disease mechanisms to identify other possible diseases for existing drugs to target.
Drug target identification
We combine our expertise in AI and biology to fully interpret histogenomic biomarkers. This helps us discover and rank genes and proteins within the innovative drug target potential.
Drug combination
Using real-world data (genomic data, clinical trial results and literature), we build AI models that analyze disease mechanisms to identify possible drug combinations. These are designed to improve the efficiency of a client's drug candidate.
Drug repurposing
We build AI models that analyze disease mechanisms to identify other possible diseases for existing drugs to target.
Drug target identification
We combine our expertise in AI and biology to fully interpret histogenomic biomarkers. This helps us discover and rank genes and proteins within the innovative drug target potential.
Drug combination
Using real-world data (genomic data, clinical trial results and literature), we build AI models that analyze disease mechanisms to identify possible drug combinations. These are designed to improve the efficiency of a client's drug candidate.
Drug repurposing
We build AI models that analyze disease mechanisms to identify other possible diseases for existing drugs to target.
Drug target identification
We combine our expertise in AI and biology to fully interpret histogenomic biomarkers. This helps us discover and rank genes and proteins within the innovative drug target potential.
Drug combination
Using real-world data (genomic data, clinical trial results and literature), we build AI models that analyze disease mechanisms to identify possible drug combinations. These are designed to improve the efficiency of a client's drug candidate.
Drug repurposing
We build AI models that analyze disease mechanisms to identify other possible diseases for existing drugs to target.
Testimonial
“Precision medicine is based on the individualization of treatment strategies based on the actual features of the patient 's tumor. Historical approaches with precision medicine have been based on single biomarkers, mostly oncogene activation. Now with Owkin, we are moving to a more comprehensive and multimodal characterization, which is needed in the setting of innovative therapies such as immunotherapies. There is a need to integrate, beyond biomarkers, features such as tumor architecture, that reflects the interactions between the tumor and the microenvironment.”
Head of Thorax Institute Curie Montsouris
Take a closer look
